ISB

Motorsports Hall of Fame of America (MSHFA) Launches Major Auction Fundraising Campaign with Lunch with GM President Mark Reuss

Retrieved on: 
Thursday, April 4, 2024
GM, Organization, Private, Celebration, IMSA GTP, ISB, 2600-series (CTA), IMSA, The Dome, Toyota Racing, Bat, Reuss, Temple University, DIS, Chevrolet Camaro, Sport, Greeting, NASCAR, Fame, Horsepower, Automotive industry

DAYTONA BEACH, Fla. , April 4, 2024 /PRNewswire/ -- The Motorsports Hall of Fame of America's blockbuster fundraiser offering a rare opportunity for a winning auction bidder to have a private one-on-one lunch with General Motors President Mark Reuss is now live an open for bidding on BringaTrailer.com

Key Points: 
  • The auction is available exclusively on automotive auction industry leader Bring a Trailer (BaT) and takes place through Tuesday, April 9th.
  • The winning bid for this no-reserve auction, including the BaT buyer's fee, will be donated to the Motorsports Hall of Fame of America (MSHFA), which is operated by a 501(c)(3) nonprofit foundation.
  • The GM Global Tech Center, which just underwent a major renovation, adds to the truly special luncheon experience with Reuss.
  • The Motorsports Hall of Fame of America is on Facebook at www.facebook.com/MotorsportsHOF/ and Instagram and Twitter at @MotorsportsHOF.

Common Immune Response Protective Across Many Diseases

Retrieved on: 
Monday, March 4, 2024
Oncology, Health, Infectious Diseases, General Health, Research, Science, Biotechnology, Paper, ISB, Cancer, Viral, Infection, Multimedia, Inflammation, Systems biology, Lupus, Cell, Death, Prevalence, Autoimmunity, Patient, Disease, NKG2C, Mortality, Immune system, Vaccine

In a just-published paper in the journal Cell Reports , Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in common ways across diseases, and offer promising avenues for exploring multi-disease therapeutic strategies.

Key Points: 
  • In a just-published paper in the journal Cell Reports , Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in common ways across diseases, and offer promising avenues for exploring multi-disease therapeutic strategies.
  • To address these challenges, ISB researchers have identified two immune cell receptors – NKG2A and NKG2C – as factors influencing immune responses across diseases.
  • Through a comprehensive analysis, they found that an NKG2A-dominant immune response correlates with decreased disease severity and mortality, and lower prevalence of post-acute chronic conditions across all disease contexts.
  • The study also identified distinct immune cell profiles associated with NKG2A and NKG2C biases, which could lead to potential therapeutic targets for modifying immune responses across diseases.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

Retrieved on: 
Wednesday, January 31, 2024
Other Health, Research, Consumer, Healthcare Reform, Parenting, Science, Baby, Maternity, COVID-19, Other Science, Health, Diabetes, Public Policy, Government, Multimedia, Multiple sclerosis, Sarcoidosis, ISB, Mother, Health information management, Vasculitis, MD, Preterm birth, Inflammatory bowel disease, Antiphospholipid syndrome, Patient, Rheumatoid arthritis, Spondyloarthropathy, Cohort (statistics), Providence, Lupus, Hypertension, Pregnancy, Autoimmunity, Thought, Risk, Psoriatic arthritis, Psoriasis, Autoimmune disease, Gestational age, Birth control

View the full release here: https://www.businesswire.com/news/home/20240131144327/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
    In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
  • Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
  • This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
  • “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

RSA Conference 2024 Innovation Sandbox and Launch Pad Contests Now Accepting Submissions

Retrieved on: 
Tuesday, January 23, 2024
SAN, RSA Conference, Initial public offering, RSA, Investment, Conference, Creativity, Imperva, ISB

SAN FRANCISCO, Jan. 23, 2024 /PRNewswire/ -- RSA Conference™, the world's leading information security conferences and expositions, today announced that submissions for the nineteenth annual RSAC Innovation Sandbox and fourth annual Launch Pad contests are now open.

Key Points: 
  • SAN FRANCISCO, Jan. 23, 2024 /PRNewswire/ -- RSA Conference™, the world's leading information security conferences and expositions, today announced that submissions for the nineteenth annual RSAC Innovation Sandbox and fourth annual Launch Pad contests are now open.
  • Submissions for the 19th annual RSA Conference Innovation Sandbox and fourth annual Launch Pad contests are now open.
  • For earlier stage companies that are not quite ready for the Innovation Sandbox stage, RSAC Launch Pad will once again be returning to the innovation programming lineup.
  • Submissions run through Thursday, February 22, 2024 with Finalists presenting at Conference on Tuesday, May 7, 2024.

ICHNOS SCIENCES DATA SELECTED FOR PRESENTATION AT THE 65TH ASH ANNUAL MEETING

Retrieved on: 
Thursday, November 9, 2023
Patient, FDA, Food, Multiple myeloma, Trace fossil classification, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, ASH, ISB, Immune system, Partnership, Abstract, Annual general meeting, Exposition, Cancer, Medical imaging, Pharmaceutical industry, Department store

NEW YORK, Nov. 9, 2023 /PRNewswire/ -- Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that three abstracts highlighting data on its leading oncology assets have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 9-12, 2023, in San Diego, California.

Key Points: 
  • Three poster presentations on three oncology assets, including clinical data on ISB 1342 and ISB 1442, and trial-in-progress data on ISB 2001
    NEW YORK, Nov. 9, 2023 /PRNewswire/ -- Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that three abstracts highlighting data on its leading oncology assets have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
  • The meeting will be held December 9-12, 2023, in San Diego, California.
  • The data to be presented will demonstrate the innovative approach of Ichnos' proprietary BEAT® platform1 to target tumor cells via the engagement of different immune cell subtypes.
  • Visit the Ichnos Sciences booth (#305) at the ASH Annual Meeting to learn more about Ichnos' proprietary BEAT® platform, expanding pipeline of assets in hematological and solid tumor malignancies, partnership opportunities and more.

Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

Retrieved on: 
Wednesday, October 25, 2023
Oncology, Health, Other Health, Other Science, Research, Science, Paper, Trial of the century, SARS-CoV-2, Antigen, TCR, Human, Professor, Cytokine, Phenotype, Protein, Multimedia, ISB, Cytomegalovirus, Disease, Immune system, National Cancer Institute, Gene, Intensive Care Foundation, Patient, Cell Reports, Memory, Vaccine

View the full release here: https://www.businesswire.com/news/home/20231025385833/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231025385833/en/
    Until now, understanding how a T cell forms into a specific role, for example a cell-killing (cytotoxic) T cell or memory T cell, has eluded us.
  • In a just-published paper in Cell Reports , ISB researchers made the breakthrough discovery that the genetically encoded T-cell receptor (TCR) sequence that humans develop in early childhood determines a T cell’s function.
  • The potential of this fundamental discovery is promising for developing custom immune responses to specific antigens.
  • In such therapies, the T cells that comprise the drug are typically engineered to aggressively kill cancer cells.

Breakthrough Study: Alzheimer’s Patients Benefit from Lifestyle Coaching (Not Drugs)

Retrieved on: 
Monday, October 16, 2023
Pillar, Functional, Health, MPI, Providence St. Joseph Health, Diet, Hearing, Risk, Dementia, Worldwide, Posit Science Corporation, Memory, Cognition, MIND, Randomized controlled trial, Medicare, Journal, FAST, COCOA, Exercise, Sleep, SAN, Grammatical mood, ISB, Attention, Patient, Quality of life, Medical imaging, Pharmaceutical industry, Dietary supplement

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- A study just published online in the Journal of Alzheimer’s Disease showed that pre-dementia and Alzheimer’s patients who received lifestyle coaching (including in using computerized brain exercises) derived cognitive benefit not generally seen in studies of Alzheimer’s drugs.

Key Points: 
  • SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- A study just published online in the Journal of Alzheimer’s Disease showed that pre-dementia and Alzheimer’s patients who received lifestyle coaching (including in using computerized brain exercises) derived cognitive benefit not generally seen in studies of Alzheimer’s drugs.
  • The brain exercises used in the study were from the BrainHQ brain training app , developed and marketed by Posit Science .
  • The study was funded by Providence St. Joseph Health as part of the health system’s Alzheimer’s Translational Pillar.
  • BrainHQ is now offered, without charge, by leading national and 5-star Medicare Advantage plans and by leading medical centers, clinics, and communities.

Personalized Coaching Decreases Cognitive Decline in Early-Stage Alzheimer’s Disease Patients

Retrieved on: 
Monday, October 16, 2023
Research, Mental Health, Neurology, Fitness & Nutrition, Clinical Trials, Telemedicine, Virtual Medicine, Biotechnology, Managed Care, Health, Science, Pillar, Functional, MPI, Diet, Standard of care, Cognition, MIND, Lecanemab, FDA, Dementia, Journal, FAST, COCOA, Cognitive deficit, Exercise, Sleep, ISB, Disability, Patient, Pharmaceutical industry, Dietary supplement

Supplementing the standard of treatment for early-stage Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of care alone, an ISB-led study shows.

Key Points: 
  • Supplementing the standard of treatment for early-stage Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of care alone, an ISB-led study shows.
  • “Over a two-year period, our trial showed that personalized lifestyle coaching in addition to standard of care decreases the amount of cognitive decline in patients on the Alzheimer’s disease spectrum,” said ISB Senior Research Scientist Dr. Jared Roach, who led the trial.
  • Personalized coaching focused on dietary recommendations based on the MIND diet, physical activity recommendations based on U.S. public health guidelines, cognitive training through BrainHQ, and recommendations for sleep and stress management.
  • “A critical next step is to test if we can further reduce patients’ cognitive decline by pairing personalized, multimodal coaching with Alzheimer’s drugs currently on the market,” Roach said.

Altysys Appoints the New Chairman of its Advisory Board

Retrieved on: 
Wednesday, September 20, 2023
Insurance, IIT, HCL, ISB, Organization, Patient, Kharagpur, HCLTech, Growth, News, DQ, Pharmaceutical industry, Headstrong

DALLAS, Sept. 20, 2023 /PRNewswire/ -- Altysys, a rapidly growing data and cloud-first startup with deep expertise in the healthcare IT consulting and services ecosystem, has appointed Arjun Malhotra as the Chairman of its advisory board.

Key Points: 
  • DALLAS, Sept. 20, 2023 /PRNewswire/ -- Altysys, a rapidly growing data and cloud-first startup with deep expertise in the healthcare IT consulting and services ecosystem, has appointed Arjun Malhotra as the Chairman of its advisory board.
  • He is widely renowned for his instrumental role in co-founding the HCL Group, way back in 1975.
  • "I am extremely excited and honored to have joined Altysys as the Chairman of the advisory board.
  • Overjoyed at sharing the news, Abhinav Mishra, the CEO of Altysys said "We are absolutely thrilled that Arjun has agreed to chair our advisory board.

ISB Researchers Find a Chink in the Armor of Tuberculosis Pathogen

Retrieved on: 
Tuesday, August 29, 2023
Research, Technology, Infectious Diseases, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Senior, Systems biology, Bill & Melinda Gates Foundation, TB, National Institute of Allergy and Infectious Diseases, Infection, Cell wall, Multimedia, Photograph, ISB, MTB, Institute for Systems Biology, Tuberculosis, Paper, Environment, Mycobacterium tuberculosis, Cell Reports, Vaccine, Pharmaceutical industry

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.

Key Points: 
  • Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.
  • Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.
  • When the network is disrupted, researchers found that Mtb’s cells are unable to properly divide, compromising their cell wall – a key defense mechanism.
  • EGRIN 2.0 identified a signaling system called MtrA that helps the pathogen grow in response to signals from a host’s body.